Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Poised To PROSPER From Xtandi In Expanded Indication

Sep 14 2017

• By Jessica Merrill

Prostate cancer blue ribbon_1200x675

Related Content

Medivation/Astellas’ <em>Xtandi</em> A Tough Rival For J&J’s <em>Zytiga</em>

Sep 10 2012

Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal

May 02 2017

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

Related Companies

Pfizer Inc.

Medivation, Inc.

Astellas Pharma, Inc.

Johnson & Johnson

Additional Topics

Clinical Trials Commercial Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window